A novel TanCAR targeting IL13Rα2 and EphA2 for enhanced glioblastoma therapy
Niaz Muhammad, Rong Wang, Wenyan Li, Zihan Zhang, Yongxing Chang, Yitao Hu, Junli Zhao, Xiaojing Zheng, Qinwen Mao, Haibin Xia
Abstract
, the novel TanCAR-redirected T cells killed glioblastoma tumor cells by recognizing either IL-13 receptor α2 (IL13Rα2) or EphA2 alone or together upon simultaneous encounter of both targets, but did not kill normal cells bearing only the IL13Rα1/IL4Rα receptor. As further proof of principle, the novel TanCAR was tested in a subcutaneous glioma xenograft mouse model. The results indicated that the novel TanCAR-redirected T cells produced greater glioma tumor regression than single CAR-T cells. Thus, the novel TanCAR-redirected T cells kill gliomas more efficiently and selectively than a single IL13 CAR or EphA2 scFv CAR, with the potential for preventing antigen escape and reduced off-target cytotoxicity.